ATS View
한국어

Celltrion Pharm KRX:068760KOSDAQ

셀트리온제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked7since Sep 11

In Q2 2026, Celltrion Pharm reported revenue of ₩153bn, up 16.8% year on year, and operating profit of ₩19.3bn. Celltrion Pharm (셀트리온제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 4 articles.

Filing signals Revenue & profit growth Screener

Celltrion Pharm quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩153bn+16.8%₩19.3bn
margin 12.6%		₩13.7bn
Q1 2026₩132bn+17.4%₩12.9bn
margin 9.8%		₩8.8bn
Q4 2025 derived₩154bn+13.9%₩13.7bn
margin 8.9%		₩8.9bn
Q3 2025₩138bn+7.8%₩16.1bn
margin 11.7%		₩11.5bn
Q2 2025₩131bn+12.1%₩15.5bn
margin 11.8%		₩11.1bn
Q1 2025₩113bn+16.0%₩10.7bn
margin 9.5%		₩7.3bn
Q4 2024 derived₩136bn+42.5%₩10.5bn
margin 7.7%		₩6.2bn
Q3 2024₩128bn+37.2%₩13.6bn
margin 10.7%		₩8.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Celltrion Pharm top stories 2 weeks, by number of outlets

  1. 1
    “간에 진짜 좋다더니”…셀트리온제약 ‘가네진’ 일부 제품 자진 회수
    2 outlets · 2 articlesFirst report Oct 23 06:00 조선비즈
  2. 2
    셀트리온제약 '가네진정' 함량 미달…긴급 자진 회수
    2 outlets · 2 articlesFirst report Oct 23 10:59 뉴스저널리즘
  3. 3
    셀트리온제약, ‘보노프라잔’ 위염 적응증 확대 추진…후발약 차별화
    1 outlets · 1 articlesFirst report Oct 20 17:25 더바이오

Latest Celltrion Pharm news Korean headlines